Sun Pharma Advanced Research Company share news and announcements
NSE: SPARCBSE: 532872Pharmaceuticals & BiotechnologySmall Cap
Last close ₹171.77down ₹1.32 (0.76%)BSE ₹171.75
Share price at the NSE close on 23 Oct 2026. Previous close ₹173.09.
52-week range of traded prices to 23 Oct 2026
₹108.00Low, 23 Mar 2026₹289.00High, 8 Jul 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹5,574 Cr778th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 3.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 18 May 2026
- 4.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 10 Aug 2026
- 118.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 84.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 18 May 2026
- 0.42
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,97,11238.6% delivered
Sun Pharma Advanced Research Company share news and announcements
583 announcements, routine notices left out, newest first. Page 6 of 12.
Oct 2020
2 Oct · Address Change
Sep 2020
Aug 2020
Jul 2020
Jun 2020
2 Jun · Board meeting
1 Jun · Management
May 2020
Mar 2020
Feb 2020
Jan 2020
31 Jan · Board meeting
Dec 2019
Nov 2019
4 Nov · Board meeting
Oct 2019
Sep 2019
3 Sep · Legal
Exchange has sought clarification from Sun Pharma Advanced Research Company Limited with respect to announcement dated 20-Aug-2019, regarding complaint filed by Abraxis Biosciences LLC. On basis of above the Company is required to clarify following: 1. Quantum of claims, if any 2. Expected financial implications, if any, due to compensation, penalty, etc. The response of the Company is awaited.
Aug 2019
Jul 2019
29 Jul · Board meeting
Jun 2019
May 2019
7 May · Board meeting